The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first drug of this type to get a green light from the European Commission to treat ...

is one of the major mechanisms of antibiotic resistance. Plasmid borne genes encoding modifying enzymes such as beta-lactamases, that confer resistance to penicillins and related antibiotics, or, more ...

Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor relebactam – has been cleared by the FDA for adults with ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...